A clinical trial involving degarelix was updated on October 22, 2026. The study, registered as NCT03703778 and titled "Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)," is listed with a status of active, not recruiting.
Degarelix is an approved compound used in the context of androgen deprivation therapy (ADT) for prostate cancer. This trial update reflects only a change in recruitment status as recorded on ClinicalTrials.gov. No phase information was provided for this study in the available record.
No results, efficacy data, or safety findings have been reported in this update. The status change indicates that enrollment has concluded or paused, but participants already enrolled may continue in the study. Readers should not interpret this status update as evidence of any outcome, benefit, or risk associated with degarelix or the ADT regimen under study.
Further details about the study design, eligibility criteria, and objectives can be found through the official trial registry listing. For additional context on degarelix as a compound, readers can consult the compound overview.